Holen Sie sich die Stockscreener-App
2.58
28.33%
-1.02
Handel nachbörslich:
2.62
0.04
+1.55%
Polaryx Therapeutics Inc Aktie (PLYX) Neueste Nachrichten
PLYX - Finviz
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) narrows loss but flags going concern risk - Stock Titan
Polaryx Therapeutics 1Q 2026: Net income $(2.54M), EPS $(0.05) — 10-Q Summary - TradingView
Polaryx Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Polaryx Therapeutics Awarded Double Honors at the 2026 GHP Healthcare & Pharmaceutical Awards - Quiver Quantitative
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards - The Manila Times
Biotech for rare pediatric lysosomal diseases wins 2 GHP awards - Stock Titan
PLYX Stock Price, Quote & Chart | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Number of shareholders of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics (NASDAQ:PLYX) Shares Down 16.3%What's Next? - MarketBeat
Polaryx Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Technical Analysis of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) - TradingView
PLYX Polaryx Therapeutics highlights rare disease pipeline progress in its newly released quarterly earnings report.Verified Stock Signals - Newser
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference - The Manila Times
Polaryx heads to Tay-Sachs family meeting with Phase 2 program - Stock Titan
FDA grants fast track status to Polaryx’s PLX-200 for three rare diseases - Investing.com Nigeria
Polaryx receives U.S. FDA Fast Track Designation for PLX-200 - TipRanks
Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate - marketscreener.com
Polaryx Therapeutics receives U.S. FDA fast track designations for all four indications to be evaluated in the Soteria Basket Trial - marketscreener.com
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial - The Manila Times
FDA fast-tracks Polaryx drug for 4 rare childhood disorders - Stock Titan
Does Polaryx Therapeutics (PLYX) Stock Pay Dividends? (Underperforming) 2026-04-20Real Trader Network - Cổng thông tin điện tử Tỉnh Sơn La
PLYX Should I Buy - Intellectia AI
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times
A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan
Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
What makes Polaryx Therapeutics (PLYX) Stock attractive or not | Price at $5.63, Down 2.26%Breakout Watch - Cổng thông tin điện tử tỉnh Lào Cai
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics, Inc. (PLYX) stock price, news, quote and history - Yahoo Finance UK
PLYX: Polaryx Therapeutics, Inc.Options Chain - Zacks Investment Research
PLYX Stock Analysis: Polaryx Therapeutics Inc. biotech gains 7.54% to hit 8.13 level - newser.com
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - Bitget
Polaryx to webcast Needham healthcare presentation on Apr. 16 - Stock Titan
Polaryx Therapeutics Inc (NASDAQ: PLYX)Share Price - intelligentinvestor.com.au
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS
Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan
PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView
MSN Money - MSN
Polaryx Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - tipranks.com
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):